GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Remedent REMI · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$1.1m

FY2015FY2024

Net income

−$307,184

FY2015FY2024

Free cash flow

−$146,084

FY2015FY2024

Shareholders' equity

$2.6m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue$1.1m$966,861$1.6m$1.2m$1.2m$1.8m$3.0m$2.6m$3.1m$4.0m
Research and development$170—$16,312——$134$2,082$9,429$9,828$68,552
Operating income−$137,549−$316,792$355,351−$36,063−$536,818−$802,921−$336,641−$1.2m$8,079$117,990
Net income−$307,184−$1.7m−$287,860−$182,556−$956,170$2.4m−$61,103$945,092$179,984$117,703
Diluted earnings per share-0.02-0.08-0.01-0.01-0.050.12-0.000.050.010.01

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$6.1m$6.3m$7.8m$8.0m$8.4m$8.8m$6.1m$5.3m$6.4m$6.2m
Cash and short-term investments$48,470$117,973$194,549$87,112$128,308$74,476$103,954$164,654$105,699$446,762
Total liabilities$3.4m$3.2m$3.0m$3.1m$3.2m$2.7m$2.4m$1.7m$3.8m$3.9m
Debt$17,327$45,165$24,999$6,106$6,106$57,209$57,954$5,607$2.5m$2.4m
Shareholders' equity$2.6m$2.9m$4.6m$4.9m$5.1m$6.0m$3.6m$3.5m$2.4m$2.3m
Shares outstanding20m20m20m20m20m20m20m20m20m20m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$146,080−$59,403−$189,101$1,926$113,661$635,327$22,752$1.9m−$227,342$336,422
Capital spending−$3—————−$5,004−$42,090−$130,184−$269,221
Free cash flow−$146,084−$59,403−$189,101$1,926$113,661$635,327$17,747$1.8m−$357,526$67,201

Latest quarters

By quarter end

Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022
Revenue$284,223$369,176$207,341$243,124$232,946$263,976$190,366$279,573
Operating income−$138,933$38,503−$9,100−$28,027−$91,390−$72,664−$161,715$8,977
Net income−$245,504$40,338−$33,028−$68,989−$557,962−$299,328−$391,492−$424,370
Diluted earnings per share-0.010.00-0.00-0.00-0.03-0.01-0.02-0.02
Total assets$6.1m$6.4m$6.1m$6.2m$6.3m$6.6m$6.8m$7.3m
Cash and short-term investments$48,470$76,219$41,096$80,738$117,973$112,885$152,024$189,593
Debt$17,327$37,963$18,919$19,487$45,165$43,425$22,235$23,552
Shareholders' equity$2.6m$2.8m$2.8m$2.8m$2.9m$3.5m$3.8m$4.2m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-1.4%-9.3%-9.2%
Operating income56.2%-29.7%-16.4%
Net income18.9%——

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-21.9%-2.8%-18.9%-15.8%
Net margin-95.6%-51.1%-13.2%3.2%

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Price to earnings-1.9-0.4-3.9-6.2-1.00.5-24.82.46.28.5
Price to sales0.50.70.71.00.80.60.50.80.40.3

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-98%-8%-44%-25%64%-16%-30%-11%59%13%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 6 Jun 2005

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.